A DEXA scan revealed a 7% drop in lean muscle mass, and Jasmine expressed concern about rebound weight gain if she ever discontinued the medication
It belongs to a novel class of drugs known as triple agonists , meaning it simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1) which reduces appetite and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) which may enhance insulin secretion and has been suggested in early studies to support fat metabolism Glucagon receptor which may increase energy expenditure and has been proposed to support fat breakdown in the liver, based on early pharmacological data [11] [12] This triple mechanism distinguishes retatrutide from existing approved medicines such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist)
In the UKPDS, sulfonylurea treatment caused a net weight gain of 3 kg, which occurred during the first 3-4 years of treatment and then stabilized [35]
With newer GLP-1based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on aging biology and to identify which patients may benefit most. Larger clinical trials will be needed to confirm these findings, determine how long the effects persist, and establish optimal dosing strategies and treatment durations for both people with HIV and the broader population
These drugs are part of a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists or GLP-1 RAs)
